Prostate Cancer and Prostatic Diseases
Papers 1687
1 page of 169 pages (1,687 results)
#1Nir Tomer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Dimple Chakravarty (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 18
Last. Ashutosh K. Tewari (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 44
view all 8 authors...
INTRODUCTION Prostate cancer (PCa) is a heterogenous disease with multiple etiological factors playing a role in its development. Recently, chronic and systemic inflammatory conditions such as inflammatory bowel disease were identified as key risk factors influencing its development. The study aimed to evaluate the relationship between diverticular disease (DD) (local and acute inflammation) and PCa. METHODS Hypertensive patients with DD and hypertensive controls were identified between 1995 and...
#1David F. Penson (VUMC: Vanderbilt University Medical Center)H-Index: 80
#2Andrew J. Armstrong (Duke University)H-Index: 63
Last. Jennifer Sugg (Astellas Pharma)H-Index: 5
view all 12 authors...
BACKGROUND In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this protocol-specified subgroup analysis of STRIVE was to investigate the benefit of enzalutamide versus bicalutamide specifically in patients with nmCRPC. METHODS Patients (N = 139) were stratified by dise...
#1Rocío Barrios-Rodríguez (UGR: University of Granada)H-Index: 4
#2Esther García-Esquinas (UAM: Autonomous University of Madrid)H-Index: 21
Last. G. Fernandez-Tardon (International Sleep Products Association)
view all 18 authors...
Some studies have reported an inverse association between type 2 diabetes mellitus (T2DM) and prostate cancer (PCa), but results on this issue are still inconsistent. In this study, we evaluate whether this heterogeneity might be related to differences in this relationship by tumour or by individual genetic susceptibility to PCa. We studied 1047 incident PCa cases and 1379 randomly selected controls, recruited in 7 Spanish provinces for the population-based MCC-Spain case-control. Tumour were cl...
#1Beatriz Silva-Ramírez (Mexican Social Security Institute)H-Index: 3
#2E J Macías-González (Mexican Social Security Institute)
Last. M Bermúdez de León (Mexican Social Security Institute)H-Index: 2
view all 10 authors...
Variants of 8q24 locus have been associated with prostate cancer (PCa) susceptibility. This study aims to analyze the genetic basis of PCa susceptibility in Mexican men by analyzing SNPs in the 8q24 locus for the first time. A case-control study was performed in 875 men recruited from the Mexican Social Security Institute, 326 patients with PCa, and 549 non-PCa patients (88 with benign prostatic hyperplasia BPH and 461 healthy controls). The 8q24 locus SNPs: rs16901979, rs16983267, rs1447295, an...
#1Hiroshi Hongo (Keio: Keio University)H-Index: 8
#2Takeo Kosaka (Keio: Keio University)H-Index: 30
Last. Mototsugu Oya (Keio: Keio University)H-Index: 56
view all 4 authors...
The taxane cabazitaxel (CBZ) is a promising treatment for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, the survival benefit with CBZ for patients with CRPC is limited. This study used screening tests for candidate drugs targeting CBZ-resistant-related gene expression and identified pimozide as a potential candidate for overcoming CBZ resistance in CRPC. We established CBZ-resistant cell lines, DU145CR and PC3CR by incubating DU145 cells and PC3 cells with gradually i...
The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine exosomes. The EPI test stratifies patients for risk of high-grade prostate cancer (HGPC; ≥ Grade Group 2 [GG] PC) in men ≥ 50 years with equivocal prostate-specific antigen (PSA) (2–10 ng/mL). Here, we present a pooled meta-analysis from three independ...
#1Klaus EredicsH-Index: 6
#2C. WehrbergerH-Index: 1
Last. M. Horetzky (Paracelsus Private Medical University of Salzburg)
view all 12 authors...
BACKGROUND Water vapor thermal therapy (Rezūm) is a minimally invasive treatment for benign prostatic enlargement (BPE). We report on safety and efficacy of this method for treatment of recurrent urinary retention and relief of catheter dependency owing to BPE in multimorbid patients, considered unfit for surgery. METHODS We retrospectively evaluated 136 patients with recurrent urinary retention who underwent water vapor therapy in an ambulatory setting with periprostatic block and optional seda...
#1E. Bass (Imperial College Healthcare)H-Index: 2
#2A PantovicH-Index: 1
Last. Hashim U. Ahmed (Imperial College Healthcare)H-Index: 62
view all 8 authors...
Background null Multiparametric MRI localizes cancer in the prostate, allowing for MRI guided biopsy (MRI-GB) 43 alongside transrectal ultrasound-guided systematic biopsy (TRUS-GB). Three MRI-GB approaches exist; visual estimation (COG-TB); fusion software-assisted (FUS-TB) and MRI 'in-bore' biopsy (IB-TB). It is unknown whether any of these are superior. We conducted a systematic review and meta-analysis to address three questions. First, whether MRI-GB is superior to TRUS-GB at detecting clini...
#1Charles Welliver (Albany Medical College)H-Index: 10
#2Lydia Feinstein (Durham University)H-Index: 10
Last. Kevin T. McVary (Loyola University Medical Center)H-Index: 68
view all 7 authors...
BACKGROUND The American Urological Association makes recommendations for evaluation and testing for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) to help primary care providers and specialists identify LUTS/BPH and harmful related conditions including urinary retention and prostate or bladder cancer. Our understanding of provider adherence to these Guidelines is limited to single-site or nonrepresentative settings. METHODS We analyzed two insurance claims d...
#1Bertrand F. Tombal (Cliniques Universitaires Saint-Luc)H-Index: 6
#2Stephen J. Freedland (Cedars-Sinai Medical Center)H-Index: 96
Last. H. Bhadauria (Astellas Pharma)
view all 14 authors...
Fatigue is a multifactorial symptom commonly reported by patients with prostate cancer as a result of disease and treatment. This study assesses the impact enzalutamide has on patient-reported fatigue (“fatigue”) by using patient-reported outcomes from four pivotal, placebo-controlled trials of enzalutamide (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVAIL (NCT01212991), and AFFIRM (NCT00974311)). Fatigue was assessed in the individual studies using the Functional Assessment of Cancer Therap...
Top fields of study
Prostate cancer
Prostate-specific antigen